1. Home
  2. FFIN vs CRNX Comparison

FFIN vs CRNX Comparison

Compare FFIN & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Financial Bankshares Inc.

FFIN

First Financial Bankshares Inc.

HOLD

Current Price

$29.95

Market Cap

4.2B

Sector

Finance

ML Signal

HOLD

Logo Crinetics Pharmaceuticals Inc.

CRNX

Crinetics Pharmaceuticals Inc.

HOLD

Current Price

$36.93

Market Cap

3.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FFIN
CRNX
Founded
1890
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.2B
3.9B
IPO Year
1994
2018

Fundamental Metrics

Financial Performance
Metric
FFIN
CRNX
Price
$29.95
$36.93
Analyst Decision
Hold
Strong Buy
Analyst Count
2
8
Target Price
$37.50
$76.63
AVG Volume (30 Days)
677.6K
1.1M
Earning Date
04-16-2026
05-07-2026
Dividend Yield
2.54%
N/A
EPS Growth
13.46
N/A
EPS
1.77
N/A
Revenue
N/A
$1,039,000.00
Revenue This Year
$17.16
$720.10
Revenue Next Year
$6.61
$184.67
P/E Ratio
$16.94
N/A
Revenue Growth
N/A
N/A
52 Week Low
$28.12
$24.10
52 Week High
$38.74
$57.99

Technical Indicators

Market Signals
Indicator
FFIN
CRNX
Relative Strength Index (RSI) 48.76 46.73
Support Level $29.44 $33.23
Resistance Level $30.21 $45.32
Average True Range (ATR) 0.66 1.68
MACD 0.18 0.50
Stochastic Oscillator 89.02 76.62

Price Performance

Historical Comparison
FFIN
CRNX

About FFIN First Financial Bankshares Inc.

First Financial Bankshares Inc is a financial and bank holding company. The company operates one line of business (community banking) located in a single geographic area (Texas). The company conducts a full-service commercial banking business through its subsidiaries. The loan portfolio segments of the company include Commercial and Industrial, Municipal, Agricultural, Construction and Development, Farm, Non-Owner Occupied and Owner Occupied Commercial Real Estate, Residential, Consumer Auto and Consumer Non-Auto.

About CRNX Crinetics Pharmaceuticals Inc.

Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.

Share on Social Networks: